The relationship between visfatin and serum concentrations of C-reactive protein, interleukin 6 in patients with metabolic syndrome
- 245 Downloads
To evaluate the relationship between inflammatory and pro inflammatory markers, with obesity and visceral adiposity in male subjects with or without metabolic syndrome (MS).
Subjects and methods
A total of 37 patients with MS and 37 age matched controls were included (mean age 46.35 ± 1.6 years). MS was defined by the criteria of the international diabetes federation 2005. Anthropometric and biochemical profiles, including high-sensitivity C-reactive protein (Hs-CRP), visfatin and interleukin 6 (IL-6), were measured. Data were compared between groups by using t test. Pearson’s correlation was used to evaluate the relationship between variables. P values less than 0.05 were considered as statistically significant.
In patients with MS, CRP and IL-6 were significantly correlated with body mass index, waist circumference and waist to hip ratio. Visfatin levels were significantly lower in patients with MS compared to controls (log visfatin: 1.74 ± 0.27 vs. 1.86 ± 0.13 ng/ml, MS vs. control group respectively). We cannot find any significant correlation between visfatin, CRP and IL-6. Also there were no correlation between visfatin levels and any anthropometric parameters in patients with MS or control groups.
Serum visfatin was lower in patients with MS. Therefore it seems that visfatin could not be considered as a pro inflammatory adipocytokine in MS. The positive associations of obesity and visceral adiposity with elevated CRP and IL-6 levels suggest the importance of reducing visceral adiposity to prevent the risk of coronary disease.
KeywordsMetabolic syndrome Visceral adiposity Visfatin IL-6 CRP
Body mass index
Coronary heart disease
Enzyme-linked immunosorbent assay
Fasting plasma glucose
High-sensitivity C-reactive protein
International diabetes federation
Tumor necrosis factor-alpha
Tehran lipid and glucose study
Waist to hip ratio
We thank all persons who participated in this study. We also thank Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences for this collaboration within the framework of the Tehran lipid and glucose study (TLGS). This piece of research was granted by Tehran University of Medical Sciences, Tehran, Iran (grant number: 6068).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The study was approved by the ethics committee of Shahid Beheshti University of Medical Sciences.
Written informed consent was obtained from all subjects.
- 1.Lorenzo C, Williams K, Hunt KJ, Haffner SM (2007) The national cholesterol education program-adult treatment panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 30(1):8CrossRefPubMedGoogle Scholar
- 3.Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J (2005) The metabolic syndrome: a global public health problem and a new definition. Vascular 7:8Google Scholar
- 14.Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19(4):972–978CrossRefPubMedGoogle Scholar
- 31.Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M et al (2009) Prevention of non-communicable disease in a population in nutrition transition: Tehran lipid and glucose study phase II. Trials 10(5):19166627Google Scholar
- 39.Wen Y, Wang H, Wu J, Lu H, Hu XF, Cianflone K (2006) Effects of fatty acid regulation on visfatin gene expression in adipocytes. Chin Med J (Engl) 119(20):1701Google Scholar